Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 4/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | TP53 | P04637 | 2/20 | 0.35 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.35 |
| ▸ | BLM | P54132 | 1/20 | 0.33 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.33 |
| ▸ | CES2 | O00748 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25148114 | 1.00 | MEN1 (0.35) | MEN1KMT2ATSHRALDH1A1TP53 | |
| SCHEMBL4952330 | 0.97 | CES2 (0.32) | MEN1KMT2ATSHRALDH1A1TP53 | |
| SCHEMBL4740546 | 0.89 | ALDH1A1 (0.30) | TSHRALDH1A1TP53HIF1AHSD17B10 | |
| SCHEMBL4947787 | 0.89 | HSD17B10 (0.38) | TSHRALDH1A1TP53HIF1AHSD17B10 | |
| SCHEMBL22940138 | 0.89 | ALDH1A1 (0.30) | TSHRALDH1A1TP53HIF1AHSD17B10 | |
| SCHEMBL5556018 | 0.87 | CA2 (0.39) | TSHRALDH1A1CES2 | |
| SCHEMBL10205493 | 0.87 | TSHR (0.40) | MEN1KMT2ATSHRALDH1A1TP53 | |
| SCHEMBL4512963 | 0.87 | CA2 (0.39) | TSHRALDH1A1CES2 | |
| SCHEMBL23451307 | 0.87 | CA2 (0.39) | TSHRALDH1A1CES2 | |
| SCHEMBL11187306 | 0.87 | ALDH1A1 (0.48) | TSHRALDH1A1TP53CES2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023061405-A1 | HIGHLY-STABLE TARGETED LINKER-DRUG CONJUGATE | 成都科岭源医药技术有限公司 | 2023-04-20 | — | — | WO | disclosed |
| US-10421843-B2 | Poly(ester amide) macromers and polymers thereof | CORNELL UNIVERSITY (US) | 2019-09-24 | — | — | US | disclosed |
| EP-2619199-A2 | CYTOSOLIC FLUORESCENT ION INDICATORS | Asante Research, LLC (US) | 2013-07-31 | — | — | EP | disclosed |
| US-20130059998-A1 | Poly(Ester Amide) Macromers and Polymers Thereof | CORNELL UNIVERSITY | 2013-03-07 | — | — | US | disclosed |
| WO-2012040204-A2 | CYTOSOLIC FLUORESCENT ION INDICATORS | ASANTE RESEARCH, LLC (US) | 2012-03-29 | — | — | WO | disclosed |
| US-20080146768-A1 | PROCESSES FOR PREPARING POLYMERS USING ALPHA,OMEGA-DIFUNCTIONAL ALDARAMIDES | E. I. DU PONT DE NEMOURS AND COMPANY | 2008-06-19 | — | — | US | disclosed |
| EP-1858955-A1 | PROCESSES USING ALPHA, OMEGA-DIFUNCTIONAL ALDARAMIDES AS MONOMERS AND CROSSLINKERS | E.I. DUPONT DE NEMOURS AND COMPANY (US) | 2007-11-28 | — | — | EP | disclosed |
| US-20060264672-A1 | Processes using alpha, omega-difunctional aldaramides as monomers and crosslinkers | E. I. DU PONT DE NEMOURS AND COMPANY | 2006-11-23 | — | — | US | disclosed |
| WO-2006091901-A1 | PROCESSES USING ALPHA, OMEGA-DIFUNCTIONAL ALDARAMIDES AS MONOMERS AND CROSSLINKERS | E.I. DUPONT DE NEMOURS AND COMPANY (US) | 2006-08-31 | — | — | WO | disclosed |
| US-6740760-B2 | SUCH AS 1-((S)-3-MERCAPTO-2-METHYL-PROPIONYL)-(R)-PYRROL-IDINE-2-CARBOXYLIC ACID FOR TREATING DISEASES ASSOCIATED WITH AMYLOIDOSIS (ALZHEIMER'S DISEASE, DIABETES, AND FAMILIAL AMYLOID POLYNEUROPATHY) | HOFFMANN-LA ROCHE INC. | 2004-05-25 | — | — | US | disclosed |
| US-5668258-A | Phenylboronic acid complexing reagents derived from aminosalicylcic acid | PROLINX, INC. (US) | 1997-09-16 | — | — | US | disclosed |
| US-5648470-A | Phenylboronic acid complexing reagents derived from aminosalicyclic acid | PROLINX, INC. (US) | 1997-07-15 | — | — | US | disclosed |
| US-5623055-A | Phenylboronic acid complexes derived from aminosalicylic acid for bioconjugate preparation | PROLINX, INC. (US) | 1997-04-22 | — | — | US | disclosed |
| US-5594111-A | Phenylboronic acid complexes for bioconjugate preparation | PROLINX, INC. (US) | 1997-01-14 | — | — | US | disclosed |
| US-5594151-A | Phenylboronic acid complexing reagents derived from aminosalicylic acid | PROLINX, INC. (US) | 1997-01-14 | — | — | US | disclosed |
| EP-0741734-A1 | PHENYLBORONIC ACID COMPLEXES | PROLINX, INC. (US) | 1996-11-13 | — | — | EP | disclosed |
| WO-1995020591-A1 | PHENYLBORONIC ACID COMPLEXES | PROLINX, INC. (US) | 1995-08-03 | — | — | WO | disclosed |
| EP-0627942-A1 | IMPROVEMENTS IN OR RELATING TO CONTRAST AGENTS | NYCOMED IMAGING AS (NO) | 1994-12-14 | — | — | EP | disclosed |
| WO-1993017718-A1 | IMPROVEMENTS IN OR RELATING TO CONTRAST AGENTS | NYCOMED IMAGING A/S (NO) | 1993-09-16 | — | — | WO | disclosed |
| US-4001298-A | RADIOPAQUE AGENTS | SCHERING AKTIENGESELLSCHAFT (DT) | 1977-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060264672-A1 | Processes using alpha, omega-difunctional aldaramides as monomers and crosslinkers | ALOX5, GSTO1, FASN | MEN1 2262/4885KMT2A 3311/4885TSHR 4512/4885 |
| US-20130059998-A1 | Poly(Ester Amide) Macromers and Polymers Thereof | PAM, PARG, MAX | MEN1 2418/4885KMT2A 851/4885TSHR 3390/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.